San Diego-based mostly Viking Therapeutics marked itself as a significant competitor during the weight loss drug marketplace in February just after revealing promising details from a mid-stage demo of experimental drug VK2735, which prompt it rivaled—and outperformed—Novo and Lilly drugs when provided as a weekly injection and in March the comp